AR087731A1 - Metodo para tratar crecimiento celular anormal - Google Patents

Metodo para tratar crecimiento celular anormal

Info

Publication number
AR087731A1
AR087731A1 ARP120102813A ARP120102813A AR087731A1 AR 087731 A1 AR087731 A1 AR 087731A1 AR P120102813 A ARP120102813 A AR P120102813A AR P120102813 A ARP120102813 A AR P120102813A AR 087731 A1 AR087731 A1 AR 087731A1
Authority
AR
Argentina
Prior art keywords
cellular growth
abnormal cellular
treating abnormal
treating
crizotinib
Prior art date
Application number
ARP120102813A
Other languages
English (en)
Inventor
Gail Christensen James
Zou Yahong
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR087731A1 publication Critical patent/AR087731A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Métodos para tratar mamíferos que padecen de cáncer mediado por al menos una ROS genéticamente alterada por medio de la administración de crizotinib.
ARP120102813A 2011-08-02 2012-08-01 Metodo para tratar crecimiento celular anormal AR087731A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161514386P 2011-08-02 2011-08-02

Publications (1)

Publication Number Publication Date
AR087731A1 true AR087731A1 (es) 2014-04-16

Family

ID=46845786

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102813A AR087731A1 (es) 2011-08-02 2012-08-01 Metodo para tratar crecimiento celular anormal

Country Status (15)

Country Link
US (1) US20160206608A1 (es)
EP (1) EP2739284A1 (es)
JP (1) JP2013032355A (es)
KR (1) KR20140041906A (es)
CN (1) CN103841972A (es)
AR (1) AR087731A1 (es)
AU (1) AU2012291744A1 (es)
BR (1) BR112014002141A2 (es)
CA (1) CA2842493A1 (es)
HK (1) HK1198133A1 (es)
IL (1) IL230698A0 (es)
MX (1) MX2014001354A (es)
RU (1) RU2014102935A (es)
TW (1) TW201313698A (es)
WO (1) WO2013017989A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
ES2637174T3 (es) 2009-02-12 2017-10-11 Cell Signaling Technology, Inc. Expresión de ROS mutante en el cáncer de hígado humano
CA2872645A1 (en) 2012-05-30 2013-12-05 Nippon Shinyaku Co., Ltd. Aromatic heterocyclic derivative and pharmaceutical
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
ITMI20131124A1 (it) 2013-07-04 2015-01-05 Univ Milano Bicocca 2-acilamminotiazoli per il trattamento del cancro
KR101538385B1 (ko) * 2013-09-02 2015-07-29 가톨릭대학교 산학협력단 크리조티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물
JP6522646B2 (ja) * 2014-03-27 2019-05-29 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＳ１阻害剤としての置換４，５，６，７−テトラヒドロ−ピラゾロ［１，５−α］ピラジン誘導体および５，６，７，８−テトラヒドロ−４Ｈ−ピラゾロ［１，５−α］［１，４］ジアゼピン誘導体
JP2017530950A (ja) * 2014-08-25 2017-10-19 ファイザー・インコーポレイテッド 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
JP7169195B2 (ja) 2016-05-20 2022-11-10 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
WO2020069118A1 (en) * 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Macrocyclic inhibitors of alk, trka, trkb, and ros1
CN115003307A (zh) 2020-02-06 2022-09-02 伟迈可生物有限公司 用于预防或治疗与kras突变相关的癌症的药物组合物
JP2023516381A (ja) 2020-03-03 2023-04-19 ウェルマーカー・バイオ・カンパニー・リミテッド Ｋｒａｓ変異および活性化ｒｏｎが存在する癌の予防または治療のための医薬組成物
WO2021196655A1 (zh) * 2020-04-03 2021-10-07 中国药科大学 含苯并咪唑结构的化合物及其制备方法与用途
CN113493437B (zh) * 2020-04-03 2022-07-26 中国药科大学 含苯并咪唑结构的化合物及其制备方法和用途
CN111518769A (zh) * 2020-05-13 2020-08-11 四川大学华西医院 一种克唑替尼获得性耐药肺腺癌细胞系的建立方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
AP2114A (en) 2003-02-26 2010-03-04 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
GEP20104906B (en) 2004-08-26 2010-02-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
EP1784396B8 (en) * 2004-08-26 2011-04-20 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
EP1973946B1 (en) 2006-01-20 2015-03-25 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
EP3741851A1 (en) 2007-10-18 2020-11-25 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
ES2637174T3 (es) 2009-02-12 2017-10-11 Cell Signaling Technology, Inc. Expresión de ROS mutante en el cáncer de hígado humano

Also Published As

Publication number Publication date
MX2014001354A (es) 2014-10-14
BR112014002141A2 (pt) 2017-02-21
IL230698A0 (en) 2014-03-31
EP2739284A1 (en) 2014-06-11
KR20140041906A (ko) 2014-04-04
RU2014102935A (ru) 2015-09-10
TW201313698A (zh) 2013-04-01
WO2013017989A1 (en) 2013-02-07
CN103841972A (zh) 2014-06-04
JP2013032355A (ja) 2013-02-14
US20160206608A1 (en) 2016-07-21
CA2842493A1 (en) 2013-02-07
HK1198133A1 (en) 2015-03-13
AU2012291744A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
AR087731A1 (es) Metodo para tratar crecimiento celular anormal
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
WO2013056148A3 (en) Scd1 antagonists for treating cancer
EP3261640A4 (en) 5ht agonists for treating disorders
UY33925A (es) Inhibidores tricíclicos de quinasas
MX357923B (es) Polipéptidos antiinflamatorios no sialilados.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY34472A (es) Derivados modificados de 4-fenil-piridina
EA201171367A1 (ru) Винилиндазолильные соединения
MY163031A (en) Method of treating obesity using antioxidant inflammation modulators
UY34661A (es) Inhibidores de benzodioxano de la producción de leucotrieno para terapia de combinación
UY34097A (es) Alineación de anticoagulante de cebado para extracción de sangre.
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
BR112013016241A2 (pt) composto, e, método para fabricar um composto
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
CL2014001719A1 (es) Metodo para tratar la perdida osea alveolar que comprende anticuerpo antiesclerostina.
UY32214A (es) Agonistas del receptor s1p para el tratamiento de malaria cerebral
CL2015002837A1 (es) Compuestos de piridinilpirazoloquinolina.
UY33976A (es) Derivados de pirazolo-pirimidina.
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
WO2013040251A3 (en) Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
CO7240413A2 (es) Composición farmacéutica que comprende fimasartan e hidroclorotiazida
UY34070A (es) Método y composición para tratamiento de semillas.
BR112013024363A2 (pt) método, e aparelho
WO2013038269A3 (en) Apparatus and methods for treating sugarcane stem cuttings

Legal Events

Date Code Title Description
FB Suspension of granting procedure